中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.108 seconds)

    Suppression of cancer metastasis
    5.
    发明专利
    Suppression of cancer metastasis 未知

    公开(公告)号：AU2010321830A1

    公开(公告)日：2012-07-05

    申请号：AU2010321830

    申请日：2010-11-19

    Applicant: ACADEMIA SINICA

    Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

    IPC: C07K14/76 ,  A61K38/16 ,  A61K38/38 ,  A61K47/48

    Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment . In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

    SUPPRESSION OF CANCER METASTASIS
    7.
    发明专利
    SUPPRESSION OF CANCER METASTASIS 未知

    公开(公告)号：CA2781433A1

    公开(公告)日：2011-05-26

    申请号：CA2781433

    申请日：2010-11-19

    Applicant: ACADEMIA SINICA

    Inventor： LIANG SHU-MEI ,  CHIU CHING-FENG ,  HUNG SHAO-WEN ,  PENG JEI-MING ,  LIANG CHI-MING

    IPC: A61K38/38 ,  A61K35/76 ,  A61K38/16 ,  A61P35/04 ,  C07K14/76

    Abstract: Methods are provided for suppressing cancer metastasis. Cancer metastasis is the most common cause of treatment failure and death in cancer patients. Tumor cell invasion and/or migration can be significantly inhibited after fibrillar proteins (rVP1, F-HSA, and F-BSA) treatment in vitro. In addition, rVP1 can significantly suppress murine and human breast cancer metastasis and human prostate and ovarian cancer metastasis in vivo while F-HSA can significantly suppress murine breast cancer metastasis. Compositions of fibrillar proteins as anti-cancer metastasis therapeutics and methods of use thereof are provided herein.

    Fibrillar fibronectin and uses thereof
    8.
    发明专利
    Fibrillar fibronectin and uses thereof 未知

    公开(公告)号：GB2460966B

    公开(公告)日：2010-05-19

    申请号：GB0913559

    申请日：2008-05-30

    Applicant: ACADEMIA SINICA

    Inventor： HUANG CHUN-YUNG ,  LIANG SHU-MEI ,  LIANG CHI-MING

    IPC: C07K14/78 ,  A61K38/39 ,  A61P35/00 ,  A61P37/04

    Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.

    Fibrillar albumin and uses thereof
    9.
    发明专利
    Fibrillar albumin and uses thereof 未知

    公开(公告)号：GB2460965B

    公开(公告)日：2010-05-19

    申请号：GB0913558

    申请日：2008-05-30

    Applicant: ACADEMIA SINICA

    Inventor： LIANG SHU-MEI ,  HUANG CHUN-YUNG

    IPC: C07K14/76 ,  A61K38/38 ,  A61P35/00 ,  A61P37/04

    Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.

    Method of producing fibrillar proteins
    10.
    发明专利
    Method of producing fibrillar proteins 未知

    公开(公告)号：GB2460283B

    公开(公告)日：2010-04-21

    申请号：GB0809919

    申请日：2008-05-30

    Applicant: ACADEMIA SINICA

    Inventor： LIANG SHU-MEI ,  HUANG CHUN-YUNG ,  LIANG CHI-MING

    IPC: C07K1/18 ,  A61K38/16 ,  A61K38/38 ,  A61K38/39 ,  A61P35/00 ,  C07K14/09 ,  C07K14/76 ,  C07K14/78

    Abstract: A conserved cluster of oligomannose glycans on gp120 has been identified as the epitope recognized by the broadly HIV-1-neutralizing monoclonal antibody 2G12. Oligomannose glycans are also the ligands for DC-SIGN, a C-type lectin found on the surface of dendritic cells. Multivalency is fundamental for carbohydrate-protein interactions, and mimicking of the high glycan density on the virus surface has become essential for designing carbohydrate-based HIV vaccines and antiviral agents. Synthesis of oligomannose dendrons, which display multivalent oligomannoses in high density, and characterize their interaction with 2G12 and DC-SIGN by a glycan microarray binding assay is disclosed. These glycodendrons inhibit the binding of gp120 to 2G12 and recombinant dimeric DC-SIGN with IC50 in the nanomolar range. A second-generation Man9 dendron was identified as a potential immunogen for HIV vaccine development and as a potential antiviral agent.

Patent Agency Ranking